Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes

Background: Decreased insulin clearance could be a relatively upstream abnormality in obesity, metabolic syndrome, and nonalcoholic fatty liver disease. Previous studies have shown that sodium-glucose cotransporter 2 inhibitor (SGLT2i) increases insulin–C-peptide ratio, a marker of insulin clearance...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Motonori Sato, Yoshifumi Tamura, Hideyoshi Kaga, Nozomu Yamasaki, Mai Kiya, Satoshi Kadowaki, Daisuke Sugimoto, Takashi Funayama, Yuki Someya, Saori Kakehi, Shuko Nojiri, Hiroaki Satoh, Ryuzo Kawamori, Hirotaka Watada
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2021-09-01
Colecção:	Biomedicines
Assuntos:	SGLT2 inhibitor insulin clearance insulin resistance ectopic fat hyperinsulinemic euglycemic clamp
Acesso em linha:	https://www.mdpi.com/2227-9059/9/9/1154
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!